Alvotech (ALVO) Expected to Announce Quarterly Earnings on Tuesday

Alvotech (NASDAQ:ALVO - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 20th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $95.02 million for the quarter.

Alvotech (NASDAQ:ALVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.52. On average, analysts expect Alvotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alvotech Price Performance

Shares of ALVO remained flat at $10.46 on Friday. The stock had a trading volume of 154,464 shares, compared to its average volume of 137,929. The firm has a market capitalization of $3.15 billion, a P/E ratio of -5.65 and a beta of -0.02. Alvotech has a fifty-two week low of $7.35 and a fifty-two week high of $14.65. The business has a fifty day moving average price of $9.40 and a 200 day moving average price of $11.31.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Alvotech stock. Goldman Sachs Group Inc. increased its stake in Alvotech (NASDAQ:ALVO - Free Report) by 40.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,444 shares of the company's stock after purchasing an additional 10,573 shares during the period. Goldman Sachs Group Inc.'s holdings in Alvotech were worth $352,000 as of its most recent SEC filing.

Analyst Upgrades and Downgrades

Separately, UBS Group initiated coverage on Alvotech in a report on Friday, February 14th. They issued a "buy" rating and a $18.00 target price on the stock.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.